Advertisement

Highlights from the 2018 European Society of Cardiology Congress in Munich, Germany

  • Dylan L. SteenEmail author
Article

After another exciting conference, this article highlights some of the many studies presented. We encourage readers to explore the broader content of the ESC presentations for other interesting studies.

Aspirin evaluation in the ASCEND trial

The ASCEND (A Study of Cardiovascular Events in Diabetes) trial studied the efficacy and safety of enteric-coated low-dose aspirin in a primary prevention population of diabetics [1]. This randomized, blinded trial sought to provide an assessment of the balance of benefits and risks associated with aspirin on top of modern diabetic treatment (e.g. statin therapy). Key eligibility criteria were: (1) diagnosis of diabetes mellitus (any type) without known cardiovascular disease; (2) equipoise regarding whether antiplatelet therapy would offer benefit; and (3) absence of any clear indication or contraindication to aspirin. The primary efficacy endpoint was death from any vascular cause (excluding intracranial hemorrhage), nonfatal myocardial...

Keywords

Scientific meetings Trials Late-breakers Cardiology 

References

  1. 1.
    ASCEND Study Collaborative Group, Bowman L, Mafham M et al (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. NEJM 379(16):1529–1539CrossRefGoogle Scholar
  2. 2.
    Ridker PM (2018) Should aspirin be used for primary prevention in the post-statin era? NEJM 379(16):1572–1574CrossRefGoogle Scholar
  3. 3.
    ASCEND Study Collaborative Group, Bowman L, Mafham M et al (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. NEJM 379(16):1540–1550CrossRefGoogle Scholar
  4. 4.
    Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. NEJM 379(11):1007–1016CrossRefGoogle Scholar
  5. 5.
    Quarta CC, Solomon SD (2018) Stabilizing transthyretin to treat ATTR cardiomyopathy. NEJM 379(11):1083–1084CrossRefGoogle Scholar
  6. 6.
    Obadia JF, Messika-Zeitoun D, Leurent G et al (2018) Percutaneous repair or medical treatment for secondary mitral regurgitation. NEJM.  https://doi.org/10.1056/NEJMoa1805374 Google Scholar
  7. 7.
    Thiele H, Akin I, Sandri M et al (2018) One-year outcomes after PCI strategies in cardiogenic shock. NEJM 379(18):1699–1710CrossRefGoogle Scholar
  8. 8.
    Thiele H, Akin I, Sandri M et al (2017) PCI strategies in patients with acute myocardial infarction and cardiogenic shock. NEJM 377(25):2419–2432CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.University of CincinnatiCincinnatiUSA

Personalised recommendations